<DOC>
	<DOCNO>NCT02432703</DOCNO>
	<brief_summary>The purpose study investigate efficacy JNJ-42165279 12 week treatment participant Social Anxiety Disorder ( SAD ) .</brief_summary>
	<brief_title>A Safety Efficacy Study JNJ-42165279 Participants With Social Anxiety Disorder</brief_title>
	<detailed_description>This Phase 2a randomize ( study drug assign chance ) , double-blind ( neither Investigator participant know study intervention ) , placebo-controlled , parallel-group , multi-center study JNJ-42165279 participant social anxiety disorder . Participants receive 25 milligram ( mg ) JNJ-42165279 match placebo orally once-daily Day 1 12 week . Participants primarily assess change baseline Liebowitz Social Anxiety Scale ( LSAS ) Week 12 . Safety monitor throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<criteria>Must primary DSM5 diagnosis Social anxiety disorder ( SAD ) except performance specifier . Participants diagnosis comorbid Generalized Anxiety Disorder ( GAD ) Major Depressive Disorder ( MDD ) may include Investigator considers SAD predominant diagnosis . Participants current lifetime history Attention deficit hyperactivity disorder ( ADHD ) specific phobia may include well Must Liebowitz Social Anxiety Scale score great equal ( &gt; = ) 70 Screening Baseline Participants current episode MDD must HDRS17 total score less equal ( &lt; = ) 18 Must body mass index ( BMI ) 18 35 kilogram per meter square ( kg/m^2 ) , inclusive , screen Female participant must either postmenopausal surgically sterile Participants performance SAD exclude . Participants current significant psychiatric condition ( ) ( Axis 1 DSMIV ) , include , limited , MDD psychotic feature ( lifetime ) , bipolar disorder ( include lifetime diagnosis ) , obsessivecompulsive disorder , borderline personality disorder , eat disorder ( e.g. , bulimia , anorexia nervosa ) , autism spectrum disorder , posttraumatic stress disorder ( PTSD ) schizophrenia exclude . Participants diagnosis comorbid GAD MDD may include Participants currently receive specific psychotherapy SAD Has history two unsuccessful adequate pharmacological treatment trial SAD , define lack response least 10 week treatment adequate dos ( e.g. , paroxetine &gt; = 40 milligram per day ( mg/day ) equivalent ; clonazepam &gt; = 2.5 mg/day equivalent ) Concurrent use psychotropic medication history current thyroid disease , thyroid dysfunction currently untreated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Social Anxiety Disorder</keyword>
	<keyword>JNJ-42165279</keyword>
</DOC>